Sai Parenteral ipo

Sai Parenteral operates in contract medicine manufacturing (CDMO) with a ₹1700 crore valuation. Promoters retain 51% after selling a large stake. The company plans capacity expansion, but the current valuation already prices in future profits. Its P/E ratio is nearly 100, far higher than peers like Sun Life Sciences (62) or Innovacabs (30). Although the business model is good, the price is too high. Investors should wait to see actual production utilization before considering long-term entry, as listing gains are unlikely.